Recombinant factor VII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 309-316

  Pfristershammer, Katharina ^a,b   Stöckl, Johannes ^a,b   Siekmann, Jürgen ^c   Turecek, Peter L ^c   Schwarz, Hans Peter ^a,c   Reipert, Birgit M ^a,c  

^a BMT Research   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BAXTER BIOSCIENCE   (Austria)

Author keywords

Danger signals; Factor VIII; FVIII inhibitors; Hemophilia A; Human dendritic cells

Indexed keywords

CD4 ANTIGEN; CYTOKINE; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8;

ANTIBODY RESPONSE; ARTICLE; BLOOD CLOTTING; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; HEMOPHILIA A; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; CHO CELL; CYTOLOGY; FLOW CYTOMETRY; HAMSTER; INFLAMMATION; METABOLISM; MONONUCLEAR CELL; T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHO CELLS; CRICETINAE; CYTOKINES; DENDRITIC CELLS; FACTOR VIII; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MONOCYTES; T-LYMPHOCYTES; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 33748586497     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-11-0729     Document Type: Article

References (33)

1. Hoyer LW. Hemophilia A. New Engl J Med 1994; 330: 39-47.
2. Hoyer, LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Inhibitors to coagulation factors. New York: Plenum 1995, 35-45.
3. Ehrenforth S, Kreuz W, Scharrer 1, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
4. Lollar P. Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX. J Thromb Haemost 2004; 2: 1082-95.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
6. Steinman RM. The control of immunity and tolerance by dendritic cells. Pathol Biol 2003; 51: 59-60.
7. Lipscomb M, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev 2002; 82: 97-130.
8. Dresser DW. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962; 5: 131-8.
9. Schlokat U, Fischer BE, Herlitschka S, et al. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furinmediated propeptide removal in vitro. Biotechnol Appl Biochem 1996; 24: 257-67.
10. Plaimauer B, Schlokat U, Tarecek PL, et al. Recombinant von Willebrand Factor: preclinical development. Semin Thromb Hemost 2001; 27: 395-403.
11. Turccek PL, Pichler L, Auer W, et al. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease. Blood 1999; 94: 1637-47.
12. Schwarz HP, Schlokat U, Mitterer A, et al. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease. Sernin Thromb Hemost 2002;28:215-26.
13. Pickl WF, Majdic O, Kohl P, et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 1996; 157: 3850-9.
14. Visintin A, Mazzoni A, Spitzer JH, et al. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001; 166: 249-55
15. Kaufman RJ, Wasley LC, Domer AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263:6352-62.
16. Hill-Eubanks DC, Parker CG, Lollar P. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA 1989;86:6508-12.
17. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochern 1986; 25: 505-12.
18. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 1957; 20: 67-9.
19. Bretscher P Cohn M. A theory of self-nonself discrimiriation. Science 1970; 169: 1042-9.
20. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
21. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
22. Peerlinck K, Arnout J, Gilles JG, et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized fector VIII concentrate. Thromb Haemost 1993; 69: 115-8.
23. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
24. Rock KL, Hearn A, Chen C-J, et al. Natural endogenous adjuvants. Springer Semin Immun 2005; 26: 231-46.
25. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-46.
26. Pulendran B: Immune activation: death, danger and dendritic cells. Current Biol 2004; 14: R30-2.
27. Lazarowski ER, Homolya L, Boucher RC, et al. Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 1997; 272:24348-54.
28. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
29. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-33.
30. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-94.
31. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195: 99-111.
32. Guillot L, Balloy V McCormack FX, et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves toll-like receptor 4. J Immunol 2002;168:5989-92.
33. Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: transducers of proteinase-mediated signalling in inflammation and immune response. Endocr Rev 2005; 26: 1-43.